Akums Drugs & Pharmaceuticals Ltd. Share Price

Akums Guides Strong FY27 with Double-Digit CDMO Growth, 14-15% Margins

Indian Market Insights – 10 August 2026

Indian equity markets are expected to remain in a consolidation phase with a neutral bias on the daily charts, while healthy sector rotation continues to support the broader market structure. The overall trend remains constructive, and a buy-on-dips approach can be considered as long as key support levels are protected. On the technical front, Nifty has strong intraday support in the 24,400–24,420 zone. Holding this area can keep the index positive and support a move towards 24,700–24,750, which remains the key resistance zone. A sustained breakout above this range could improve momentum further. Bank Nifty has also remained range-bound over the past few sessions and is likely to continue consolidating in today’s trade. Key support is placed around 57,100–57,250, while immediate resistance is seen at 58,200–58,250, followed by 58,500. From the derivatives perspective, FIIs created fresh short positions during Friday’s session, so today’s closing price action will be important. Traders should closely monitor whether these shorts continue to build or start getting covered, as this could influence the next directional move. Key Cues for Today Positive: Strong U.S. jobs data could support global risk sentiment. Negative: Rising crude oil prices remain a concern, particularly for oil-importing economies like India, as higher crude can impact inflation and corporate margins. Stocks to Watch

Akums Drugs Reports Strong Q1 FY27 Results

Key Highlights Akums Drugs reported a strong Q1 FY27 performance, with robust growth in Net Profit, Revenue, and EBITDA on a YoY basis. The company also delivered a significant improvement in its EBITDA Margin, indicating stronger operating profitability. Financial Performance • Net Profit: ₹100 Crore, up 58.7% YoY from ₹63 Crore. • Revenue: ₹1,167 Crore, up 14% YoY from ₹1,024 Crore. • EBITDA: ₹175 Crore, up 35.7% YoY from ₹129 Crore. • EBITDA Margin: 15.0% vs 12.6%, up 240 bps YoY. What It Means • Double-digit revenue growth indicates continued business expansion during the quarter. • Stronger EBITDA growth compared with revenue reflects improved operating profitability. • The 240 bps margin expansion indicates better operating efficiency and profitability. Market Impact Impact: Positive The strong growth in net profit and EBITDA, combined with significant margin expansion, indicates healthy improvement in operating performance. The results are likely to support positive investor sentiment. Learning Outcome Margin Expansion occurs when a company's profit margin increases over time. When EBITDA grows faster than revenue, it can lead to higher EBITDA Margin, indicating that the company is converting a larger portion of its revenue into operating earnings.

Akums Drugs Acquires Oriflame India’s Manufacturing Business for ₹56 Crore

Akums Drugs and Pharmaceuticals Limited, through its subsidiary Pure and Cure Healthcare, has agreed to acquire the manufacturing business of Oriflame India Private Limited for an all-cash consideration of ₹56 crore. The transaction was finalized on July 23, 2026, with completion expected by August 31, 2026. Key Deal Highlights: Assets Acquired: Two manufacturing plants (Roorkee, Uttarakhand and Noida, Uttar Pradesh) and a leased warehouse facility in Noida. Strategic Rationale: This move marks Akums’ strategic entry into the color cosmetics market, significantly expanding its existing footprint in the skincare and wellness segments while instantly boosting its manufacturing capacity. Key Exclusion: The deal is strictly for the manufacturing assets; it does not include the trademark or marketing rights for Oriflame’s products in India. Strategic Outlook: This acquisition allows Akums to rapidly capitalize on the high-growth Indian cosmetics and personal care market. By securing established, ready-to-use manufacturing infrastructure, the company can accelerate its contract manufacturing (CDMO) offerings, diversify its revenue streams beyond traditional pharmaceuticals, and strengthen its position as a comprehensive health and wellness manufacturing partner.

Akums Drugs & Pharmaceuticals (AKUMS) – Technical Price Action Analysis

Akums Drugs & Pharmaceuticals (AKUMS) – Technical Price Action Analysis Current Market Price (CMP): ₹610 Akums has shown a strong recovery from its recent lows near ₹410-450 and is now trading close to its 52-week high zone of around ₹623. The stock has been one of the stronger performers in the pharma/CDMO space recently. Technical View: Stock is trading above key short, medium, and long-term moving averages, indicating a bullish trend. Recent breakout above the ₹590-600 resistance zone suggests fresh buying interest. Volume expansion during the upmove indicates institutional participation. Momentum remains positive as long as the stock sustains above ₹585-590. Key Levels Immediate Support: ₹595 Strong Support: ₹575 Positional Support: ₹550 Immediate Resistance: ₹623 Next Resistance/Target: ₹650 Extended Target: ₹680-700 Trading Strategy ✅ Bullish above ₹595 Target 1: ₹650 Target 2: ₹680 Stop Loss: ₹575 (closing basis)

AKUMS Drugs & Pharmaceuticals Ltd. (NSE: AKUMS)